Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
Clinical trial NCT01752634 · COMPLETED
Trial details
- NCT number
- NCT01752634
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-04-14
- Primary completion
- 2014-05-12
- Enrollment
- 397
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.